Your provider can help you decide whether a maintenance dose, a trial pause, or indefinite continuation best fits your health goals and weight-loss history
Recent clinical wins include: Taltz + Zepbound combination: Delivered superior efficacy in adults with psoriatic arthritis and obesity Orforglipron: Helped patients maintain weight loss after switching from injectables to oral therapy a potentially massive market expansion Retatrutide: The companys triple agonist delivered average weight loss of 71.2 pounds along with substantial osteoarthritis pain relief The orforglipron data matters particularly for the competitive landscape
Unfortunately, many of our favorite summertime activities, such as visiting the beach or park, can bring large groups of people together and put you or your loved ones at a higher risk for infection. While enjoying the sunshine and fresh air this summer, its important to use common sense when venturing into public spaces, Dr
Gastrointestinal side effects were common among recipients of the once-weekly GLP-1 agonist
For example, were bringing behavioral health into primary care, cardiac care, pediatrics and womens health
There were also no differences in metabolic glucose clearance, alanine turnover, urea synthesis and glucose formation by gluconeogenesis using alanine as precursor